J&J gets a quick FDA OK for its block­buster pso­ri­a­sis con­tender guselkum­ab

Just four months af­ter rolling out its last batch of promis­ing late-stage da­ta, J&J has scored a quick OK for guselkum­ab as a new treat­ment for pso­ri­a­sis, one of the top drug prospects in the in­dus­try’s late-stage pipeline.

The IL-23 drug will now be com­mer­cial­ized as Trem­fya, says the phar­ma gi­ant, which tapped this drug as one of its most im­por­tant Phase III prod­ucts. To get the OK this fast, J&J says it used a pri­or­i­ty re­view vouch­er, an in­cen­tive that’s be­come a pricey com­mod­i­ty in the bio­phar­ma mar­ket as de­vel­op­ers turn to them for slash 4 months off the FDA’s re­view process.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN